1. Scrip
  2. >>Business

AZ names Steve Twait VP, alliance and integration

 
• By Lucie Ellis-Taitt

Steve Twait has joined AstraZeneca's business development leadership team in a newly created role – vice-president of alliance and integration management. Mr Twait joins AstraZeneca from Eli Lilly's alliance management and M&A integration group, where he founded the Office of Alliance Management. At Lilly he played a leading role in the integration of global partnerships with Bristol-Myers Squibb, Boehringer Ingelheim, and Daiichi Sankyo. Mr Twait will be based at the company's Cambridge, UK site.

Steve Twait has joined AstraZeneca's business development leadership team in a newly created role – vice-president of alliance and integration management. Mr Twait joins AstraZeneca from Eli Lilly's alliance management and M&A integration group, where he founded the Office of Alliance Management. At Lilly he played a leading role in the integration of global partnerships with Bristol-Myers Squibb, Boehringer Ingelheim, and Daiichi Sankyo. Mr Twait will be based at the company's Cambridge, UK site.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

Finance Watch: A Mini-Surge In Follow-On Offerings Follows Positive Updates

 
• By Mandy Jackson

Public Company Edition: A breakthrough designation, data and deals prompted big follow-on public offerings in late June and early July, including $402.5m for Cidara, $250.8m for Kymera and $230m for Dyne. Also, Revolution Medicines accessed up to $2bn from Royalty Pharma.

KalVista’s Delayed FDA Approval In HAE Comes Through

 
• By Joseph Haas

KalVista’s Ekterly obtains US approval as the first oral, on-demand therapy for hereditary angioedema. It will compete with established injectables.

Cogent Peaks With Bezaclastinib SUMMIT Results

 
• By Alaric DeArment

The biotech announced positive topline results from the Phase II SUMMIT study in non-advanced systemic mastocytosis, with data for advanced SM and GIST expected later this year.

France’s AB Science Plots Pivotal Masitinib Trial In Prostate Cancer

 
• By Kevin Grogan

Still holding out hope after multiple rejections for the tyrosine kinase inhibitor.

More from Scrip